GLPwatch

Therapeutic effect of liraglutide on expression of CTGF and BMP-7 in induced diabetic nephropathy.

J Cell Biochem · 2019

Last updated 2026-05-28

In a study of 60 rats with diabetes-related kidney disease, those given the GLP-1 drug liraglutide showed improvements in kidney function and structure. Liraglutide reduced a harmful protein (CTGF) by 30% and increased a protective protein (BMP-7) by 40%, while also lowering blood sugar and markers of kidney damage.

AI summary of the abstract below.

JournalJ Cell Biochem, 2019
Citations2
Relative citation ratio0.10
NIH percentile7
Molecules liraglutide
Conditions studied Type 2 Diabetes, Chronic Kidney Disease

Abstract

INTRODUCTION: Diabetic nephropathy (DN) is one of the critical complications of diabetes mellitus and the main cause of chronic renal dysfunction. The pathogenic mechanism causing the disease remains unclear and there is a lack of effective treatment methods so novel strategies are needed for DN management. The aim of this study, therefore, is to evaluate the effect of liraglutide as glucagon-like peptide-1 analogue and its underlying mechanisms on induced DN in rats MATERIALS AND METHODS: Sixty rats were divided into control group, diabetic group, and liraglutide-treated group. At the end of experiment, renal CTGF and BMP-7 messeger RNA expression were determined. Blood sugar, serum urea, and creatinine were measured. Also, histopathological changes were studied. RESULTS: Liraglutide can improve renal alterations associated with diabetes as it reduced CTGF expression and increased BMP-7 expression. In the same time, it could improve histopathological changes and renal function tests. CONCLUSION: These findings influence the beneficial use of liraglutide for the management of DN in patients with diabetes mellitus.

Verbatim abstract via PubMed 31127659 ↗

Related research